ONCOLYTIC-HERPES

ONCOLYTIC HERPESVIRUSES RETARGETED TO CANCER- SPECIFIC RECEPTORS

 Coordinatore ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Italy [IT]
 Totale costo 2˙477˙346 €
 EC contributo 2˙477˙346 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2013-ADG
 Funding Scheme ERC-AG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-03-01   -   2019-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI GENOVA

 Organization address address: VIA BALBI 5
city: GENOVA
postcode: 16126

contact info
Titolo: Dr.
Nome: Loredana
Cognome: Pacetti Merlini
Email: send email
Telefono: +39 010353 7599
Fax: +39 010353 8402

IT (GENOVA) beneficiary 69˙600.00
2    UNIVERSITA DEGLI STUDI DI VERONA

 Organization address address: VIA DELL ARTIGLIERE 8
city: VERONA
postcode: 37129

contact info
Titolo: Dr.
Nome: Enrico
Cognome: Cazzaroli
Email: send email
Telefono: +39 045 8126446

IT (VERONA) beneficiary 36˙000.00
3    ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA

 Organization address address: Via Zamboni 33
city: BOLOGNA
postcode: 40126

contact info
Titolo: Mrs.
Nome: Luisa
Cognome: Romagnoli
Email: send email
Telefono: +39 051 6364971
Fax: +39 051 397738

IT (BOLOGNA) hostInstitution 2˙371˙746.00
4    ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA

 Organization address address: Via Zamboni 33
city: BOLOGNA
postcode: 40126

contact info
Titolo: Prof.
Nome: Maria Gabriella
Cognome: Campadelli
Email: send email
Telefono: +39 051 2094733
Fax: +39 051 2094735

IT (BOLOGNA) hostInstitution 2˙371˙746.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

attenuated    killing    oncolytic    patients    ovary    immunity    hsvs    infect    retargeted    health    aim    cancer    engineer    hsv    normal    viruses    her    clinical    cells    breast   

 Obiettivo del progetto (Objective)

'Cancer remains a major health burden worldwide. The aggressive targeting of metabolic pathways shared by normal and cancer cells results in prolonged survival and cures, but at a tremendous cost to patient life quality. What is missing is a therapeutic agent that clearly differentiates normal and cancer cells. This proposal delineates a process for killing exclusively cancer cells with no interference with normal cells. In the past two decades there has been considerable effort to develop attenuated viruses for killing cancer cells. Of the oncolytic viruses in clinical trials, attenuated herpes simplex viruses (HSV) are among the most promising because of safety, affinity for cancer cells, ability to treat patients multiple times without block by adaptive immunity. The shortcoming is that they do not discriminate between normal and cancer cells, are effective in a limited number of patients. The remarkable accomplishment by my laboratory at the basis of the proposal is the genetic engineering of HSVs that specifically infect and kill cancer cells and cannot infect normal cells. The prototype retargeted HSV targets HER2, a receptor in breast, ovary and other tumors. HER2-HSV ablates human breast and ovary cancers, and glioblastoma after intratumoral or intraperitoneal administration. This proposal addresses basic research issues for the advancement of retargeted oncolytic HSVs. It is organized in 5 AIMS • Engineer a non-cancer cell line for virus production acceptable to Health Authorities and re-engineer the retargeted-HSV accordingly. This will enable production of clinical grade retargeted-HSVs for clinical tests (AIM1) • Engineer retargeted-HSVs suitable for systemic delivery and for boosting anti-tumor immunity (AIM2-3) • Apply our platform to expand the repertoire of oncolytic HSVs that target glioblastomas, prostate, head-and-neck, colon carcinomas (AIM4) • Determine the tumorigenic potential of cancer cells that escape killing by retargeted HSVs (AIM5)'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

ERACEP (2009)

Emerging Research Areas and their Coverage by ERC-supported Projects

Read More  

MISTS (2013)

Market-Based Initiatives as Solutions to Techno-Scientific Problems

Read More  

ARENA (2009)

Arrays of entangled atoms

Read More